These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33287648)

  • 1. CTNNB1 Knockdown Inhibits Cell Proliferation and Aldosterone Secretion Through Inhibiting Wnt/β-Catenin Signaling in H295R Cells.
    Zhou T; Luo P; Wang L; Yang S; Qin S; Wei Z; Liu J
    Technol Cancer Res Treat; 2020; 19():1533033820979685. PubMed ID: 33287648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutations in CTNNB1 in aldosterone producing adenomas.
    Åkerström T; Maharjan R; Sven Willenberg H; Cupisti K; Ip J; Moser A; Stålberg P; Robinson B; Alexander Iwen K; Dralle H; Walz MK; Lehnert H; Sidhu S; Gomez-Sanchez C; Hellman P; Björklund P
    Sci Rep; 2016 Jan; 6():19546. PubMed ID: 26815163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colocalization of Wnt/β-Catenin and ACTH Signaling Pathways and Paracrine Regulation in Aldosterone-producing Adenoma.
    De Sousa K; Abdellatif AB; Giscos-Douriez I; Meatchi T; Amar L; Fernandes-Rosa FL; Boulkroun S; Zennaro MC
    J Clin Endocrinol Metab; 2022 Jan; 107(2):419-434. PubMed ID: 34570225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
    Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
    Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production.
    Berthon A; Drelon C; Ragazzon B; Boulkroun S; Tissier F; Amar L; Samson-Couterie B; Zennaro MC; Plouin PF; Skah S; Plateroti M; Lefèbvre H; Sahut-Barnola I; Batisse-Lignier M; Assié G; Lefrançois-Martinez AM; Bertherat J; Martinez A; Val P
    Hum Mol Genet; 2014 Feb; 23(4):889-905. PubMed ID: 24087794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
    Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
    PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
    Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. lncRNA FLVCR1-AS1 silencing inhibits lung cancer cell proliferation, migration, and invasion by inhibiting the activity of the Wnt/β-catenin signaling pathway.
    Lin H; Shangguan Z; Zhu M; Bao L; Zhang Q; Pan S
    J Cell Biochem; 2019 Jun; 120(6):10625-10632. PubMed ID: 30697812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
    Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
    Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
    Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
    Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AXIN genetic analysis in adrenocortical carcinomas updated.
    Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
    J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Characterization of GnRH/LH-Responsive Primary Aldosteronism.
    Gagnon N; Cáceres-Gorriti KY; Corbeil G; El Ghoyareb N; Ludwig N; Latour M; Lacroix A; Bourdeau I
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2926-2935. PubMed ID: 29726953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes.
    Wu VC; Wang SM; Chueh SJ; Yang SY; Huang KH; Lin YH; Wang JJ; Connolly R; Hu YH; Gomez-Sanchez CE; Peng KY; Wu KD
    Sci Rep; 2017 Jan; 7():39121. PubMed ID: 28102204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
    Chapman A; Durand J; Ouadi L; Bourdeau I
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.
    Zhou J; Azizan EAB; Cabrera CP; Fernandes-Rosa FL; Boulkroun S; Argentesi G; Cottrell E; Amar L; Wu X; O'Toole S; Goodchild E; Marker A; Senanayake R; Garg S; Åkerström T; Backman S; Jordan S; Polubothu S; Berney DM; Gluck A; Lines KE; Thakker RV; Tuthill A; Joyce C; Kaski JP; Karet Frankl FE; Metherell LA; Teo AED; Gurnell M; Parvanta L; Drake WM; Wozniak E; Klinzing D; Kuan JL; Tiang Z; Gomez Sanchez CE; Hellman P; Foo RSY; Mein CA; Kinsler VA; Björklund P; Storr HL; Zennaro MC; Brown MJ
    Nat Genet; 2021 Sep; 53(9):1360-1372. PubMed ID: 34385710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
    Maharjan R; Backman S; Åkerström T; Hellman P; Björklund P
    Sci Rep; 2018 Jun; 8(1):8610. PubMed ID: 29872083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.